A major focus in the study of metabolism and disposition of trichloroethylene (TCE) is to identify metabolites that can be used reliably to assess flux through the various pathways of TCE metabolism and to identify those metabolites that are causally associated with toxic responses. Another important issue involves delineation of sex-and species-dependent differences in biotransformation pathways. Defining these differences can play an important role in the utility of laboratory animal data for understanding the pharmacokinetics and pharmacodynamics of TCE in humans. Sex-, species-, and strain-dependent differences in absorption and distribution of TCE may play some role in explaining differences in metabolism and susceptibility to toxicity from TCE exposure. The majority of differences in susceptibility, however, are likely due to sex-, species-, and strain-dependent differences in activities of the various enzymes that can metabolize TCE and its subsequent metabolites. An additional factor that plays a role in human health risk assessment for TCE is the high degree of variability in the activity of certain enzymes. TCE undergoes metabolism by two major pathways, cytochrome P450 (P450)-dependent oxidation and conjugation with glutathione (GSH). Key P450-derived metabolites of TCE that have been associated with specific target organs, such as the liver and lungs, include chloral hydrate, trichloroacetate, and dichloroacetate. Metabolites derived from the GSH conjugate of TCE, in contrast, have been associated with the kidney as a target organ. Specifically, metabolism of the cysteine conjugate of TCE by the cysteine conjugate ,B Iyase generates a reactive metabolite that is nephrotoxic and may be nephrocarcinogenic. Although the P450 pathway is a higher activity and higher affinity pathway than the GSH conjugation pathway, one should not automatically conclude that the latter pathway is only important at very high doses. A synthesis of this information is then presented to assess how experimental data, from either animals or from in vitro studies, can be extrapolated to humans for risk assessment.
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A scheme summarizing the major metabolic pathways for TCE is shown ( Figure 1 In Vivo Absorption and Distribution of TCE As a result of its chemical properties (e.g., volatility, lipophilicity), TCE is readily absorbed across biological membranes. For human exposures, TCE is considered to be an eye and skin irritant. There are essentially three types of exposures to consider for humans or laboratory animals: inhalation, dermal, and oral. Exposure is usually either from TCE vapor or from TCE liquid. In either form, TCE is rapidly and extensively absorbed through the lungs or gastrointestinal tract, respectively. Absorbed TCE is then subsequently distributed to different target organs (e.g., lungs, liver, kidneys, nervous system) via the circulatory system.
After inhalation exposure, TCE is rapidly and extensively absorbed through the alveolar endothelium due to a high blood/gas partition coefficient. Although absorption is high in all cases, blood/gas partition coefficients vary significantly among species (Table 1) . Since the blood/gas partition coefficient in humans is approximately 1.5-and 2.5-fold lower than that in mice and rats, respectively, This article is part of the monograph on Trichloroethylene Toxicity. this suggests that delivery of TCE to the circulatory system for translocation to target organs may be significantly less efficient in humans than in rodents and is a factor that may need to be taken into account when using animal data in a risk assessment analysis for TCE.
Dermal absorption from exposure to TCE vapor is negligible, although direct skin contact with TCE liquid may lead to significant absorption. Since a large proportion of the TCE that is absorbed dermally in humans is excreted unchanged through the lungs and this is not the usual route of exposure to TCE, dermal absorption is not considered to be a major factor in the risk assessment analysis (3) . These data have been reviewed by Davidson and Beliles (4) . It should be noted, however, that a study of dermal absorption of dilute, aqueous solutions of TCE and similar organic solvents in hairless guinea pigs indicated that significant absorption occurs (5 given an intragastric dose (18 mg/kg) in water was nearly 15-fold higher than those in rats given the same dose in the same volume of corn oil (14.7 vs 1.0 pg/mL). Hence, the authors concluded that gastrointestinal absorption of TCE can be limited by the absorption of the vehicle. The vehicle used in exposures in animal studies, therefore, needs to be taken into account when extrapolating animal exposure data for human health risk assessment.
As a consequence of differences in blood flow and overall metabolic rate, species differences exist in the fraction of administered dose of TCE that is available for conversion (163) 9.2 (164) SD, Sprague-Dawley. Blood samples were taken by cardiac puncture and were analyzed by gas chromatography. AUC were determined graphically up to the final time point taken (TCE: 7.5 hr in rats, 11 hr in mice; CH: 15 hr in rats, 10 hr in mice; TCOH: 18 hr in rats, 8 hr in mice; TCA: 40 hr in rats, 44 hr in mice). For TCA in mice, two major peaks of blood concentration were observed. Data originally reported in Prout et al. (7) .
Environmental Health Perspectives * Vol 108, Supplement 2 * May 2000 similarly higher peak plasma concentrations of TCA in male and female mice compared with male and female rats. These observations have important implications for species differences in susceptibility to toxicity. As discussed in the review on mode of action in the liver (9) , TCA is believed to be the primary TCE metabolite responsible for liver injury and proliferation. The markedly higher blood concentrations of TCA in mice compared with rats indicate that more TCA will get to the target organ in mice and are consistent with the male mouse as the sex and species that is the most susceptible to liver injury and carcinogenesis.
In analyzing the distribution of TCE into various tissues, three major compartmental tissue groups can be identified: richly perfused (e.g., liver, kidneys, lung), poorly perfused (e.g., muscle), and adipose tissue. TCE readily equilibrates from the circulation into richly perfused tissues, with reported partition coefficients for liver:blood or richly perfused tissue:blood for male rats of approximately 1.2 (8,10) . Partition coefficients for female rats (1.46) and for male and female mice (2.03 and 1.62, respectively) are modestly higher than those in male rats (8) , but these modest differences are not likely to be major factors in the sex-and species-dependent differences in TCE-induced toxicity. Muscle:blood partition coefficients for TCE have been reported to be less than 0.5 for male and female rats and female mice and 1.00 for male mice (8, 10) . Hence, muscle is neither a major site of storage nor a major site of metabolism of TCE and does not significantly influence TCE pharmacokinetics or pharmacodynamics.
Although the adipose tissue:blood partition coefficient does not differ greatly among male and female rats and mice, with reported values ranging between 25 and 41 (8) , the fact that it is so high indicates that sequestration of TCE in fat may have a major influence on the pharmacokinetics of TCE. In fact, the half-life of TCE in adipose tissue is estimated to be 3.5-5 hr, whereas that in both the richly and poorly perfused compartments is estimated to be 2-4 min (4 Daniel (12) dosed rats by stomach tube (60 mg/kg) with labeled TCE and reported that 90-95% of the radiolabel was recovered in expired air and urine. Dekant et al. (13) gavage-dosed mice and rats with 200 mg/kg of labeled TCE in corn oil and recovered 93-98% of the radiolabel. Prout et al. (7) administered several doses of labeled TCE (10-2,000 mg/kg) to rats and mice and recovered 93-98% of the radiolabel and reported that peak blood levels occurred in 1 hr in mice and 3 hr in rats. D'Souza et al. (14) , using classical pharmacokinetic analysis, reported that oral and intravenous bioavailability of TCE was 60-90% in nonfasted rats and greater than 90% in fasted rats. Peak blood levels occurred between 6-10 min and blood concentrations were 2-3 times higher in the fasted rats compared with the nonfasted rats. Lee et al. (15) (17) .
Inhalation of TCE results in very rapid uptake of TCE into the systemic circulation in animals (8) and humans (18) , although the time required to reach peak blood concentrations differs across species. Peak blood concentrations of TCE are achieved within 1-2 hr in mice exposed to 100-750 ppm-TCE vapors, in 4-6 hr in rats exposed to 500-600 ppm TCE vapors, and in 8-12 hr in humans exposed to 100 ppm TCE.
Once TCE is in the systemic circulation, TCE is oxidized (metabolized) rapidly. Using PBPK models, estimates of metabolic capacity have been determined in rodents and humans, and are summarized in The plasma half-life values for TCA are much shorter in rodents than in humans. In rats given intravenous administration of TCA (5-6 mg/kg), the TCA plasma half-lives were 12 and 7 hr in males and females, respectively (8) . In mice given intraperitoneal doses of TCA (5-10 mg/kg), the plasma half-lives for TCA were 7 and 3 hr for males and females, respectively (8) . In mice exposed to TCE vapors (42-889 ppm) for 4 hr, the estimated plasma half-life values for TCA were 16 and 7 hr for males and females, respectively (8) . In male and female rats exposed to TCE vapors (500-600 ppm), the estimated half-life value for TCA in plasma was 15 hr (20) .
The residence time for free TCOH in blood is less than the residence time in plasma for TCA in rodents and humans. The half-life of free TCOH in blood is about 12 hr in humans exposed to 50 ppm TCE vapors 6 hr per day for 5 days (21) and is 3 hr in mice administered 1, 200 mg/kg TCE via oral bolus intubation (22) . Two other oxidative end products readily found in blood of mice administered TCE that are not readily measured in human blood are chloral hydrate and trichloroethanol glucuronide. CH and TCOH glucuronide (TCOG) were not measured in humans exposed to 100 ppm TCE for 4 hr (19) . In mice gavage-dosed with 1,200 mg/kg of TCE, the blood half-life values for CH and TCOG were 3 and 5 hr, respectively (22) .
Oxidative Pathways of TCE Metabolism
This section describes each step of the oxidative pathway of TCE metabolism and identifies key metabolites that are thought to be important for development of toxicity or carcinogenesis. Although many of the enzymes that catalyze the specific steps of this pathway are distributed fairly ubiquitously, a range of activity levels of specific isozymes is found in the different target tissues or in a given tissue in males and females from various species, which can markedly alter the distribution of metabolites that are formed. This, in turn, may have mechanistic implications as tissueand/or sex-and/or species-specific accumulation of certain metabolites can produce toxic responses that are not otherwise observed.
Descrption ofOxidative Pathways ofTCE Metabolism
Role offormation of TCE-epoxide in oxidative metabolism of TCE. Although TCE is a chemically simple compound, its metabolism is rather complex. The initial step in TCE metabolism, as described above (Figure 1) , is either conjugation with GSH (discussed below) or oxidation by P450. The oxidative pathway is quantitatively by far the major pathway for TCE metabolism and the liver is the primary tissue where this step takes place, although P450 isoforms are present in most tissues in varying forms and amounts. The initial step in the oxidative metabolism of many halogenated alkenes is epoxidation (23) . Hence, the biotransformation of TCE to a reactive epoxide intermediate (2,2,3-trichlorooxirane) was proposed many years ago (24, 25 (28) . Miller and Guengerich (27) concluded that the species that irreversibly binds to protein and DNA during TCE metabolism must have, unlike an epoxide, a reasonable degree ofchemical stability. Hence, the current dogma is that the majority ofTCE is believed to undergo chlorine migration in an oxygenated TCE-P450 transition state leading to CH formation. However, Forkert and co-workers (29-32) have provided substantial evidence that 1,1 -dichloroethylene, which is very similar to TCE, is metabolized by P450 to an epoxide intermediate. These findings suggest that the role of the epoxide in TCE metabolism should be revisited (see discussion under "Questions and Research Needs" below).
The previous conclusion in the last U.S. Environmental Protection Agency risk assessment for TCE (33) (43, 44) , and this has been attributed to the accumulation of CH, which occurs because the subsequent steps in the metabolism of CH are much slower than the conversion of TCE to CH (45) . Besides having a slow rate of subsequent metabolism of CH, the rate of formation of CH in mouse lung is markedly higher than that in either rat or human lung (44) . CH CH reduction to TCOH has been reported to be inhibited by ethanol, and it was suggested that this reaction is, therefore, catalyzed by alcohol dehydrogenase (47, 48 (59) identified DCA, in addition to TCA, TCOH, and TCOG, as a metabolite of CH in children, for whom CH is still used therapeutically as a sedative-hypnotic agent. Nonetheless, more DCA is formed in mice than in other species. It is difficult, therefore, to develop parameters for DCA formation that can be used in PBPK models for human health risk assessment. Since both DCA and TCA produce hepatomegaly and cytomegaly that may lead to hepatocarcinogenesis (54, 56) and DCA is derived from both TCA and TCOH, assumptions need to be made until a more definitive verdict on the formation of DCA in humans is made. However, both DCA and TCA are unequivocally hepatocarcinogenic, irrespective of their mechanism or mode of action (54) .
An errata was published based on the studies of Templin et al. (57) Quantitatively, the liver is the most important site of oxidative metabolism of TCE due to the first-pass effect. Regardless of the route of administration (i.e., dermal, inhalation, oral), most of the TCE is rapidly absorbed into the circulation and goes to the liver. Only in specialized circumstances does the liver not play a key role or at least some role in determining overall metabolism and toxicity.
A situation where differential activities of the enzymes of the oxidative pathway of TCE metabolism markedly affect the distribution of metabolites and the toxicity is that of CH accumulation in mouse lungs (44, 45) . Clara cells of mouse lungs have relatively high P450 activity but have low activities of alcohol dehydrogenase and UDP-glucuronosyltransferase. Hence, the enzymes that metabolize CH and TCOH are believed to be present in low amounts relative to P450, leading to an accumulation of CH in the cells. Since TCOH is recovered in significantly greater amounts and as a higher fraction of total TCE metabolites in mice than in other species, UDP-glucuronosyltransferase may be present at relatively low levels compared to the other enzymes involved in oxidative metabolism of TCE, not only in the mouse lung, but in other mouse tissues as well, including the liver.
Besides the liver, the kidneys may be directly exposed to TCE or some of its metabolites, since they receive 25% of the cardiac output. While the kidneys contain P450 activities, induding CYP2E1 (at least in rodents), most of it is in the proximal tubules and the total activity in the tissue as a whole is markedly lower than that in the liver.
Nonetheless, renal oxidative metabolism of TCE occurs, albeit at rates that are 3-to 10- fold lower than those in the liver (63) As described in the reviews on mode of action in the various target organs, marked differences in susceptibility to TCE-induced toxicity are seen in males and females of each species and between species of a given sex. Since toxicity is directly associated with specific metabolites, the likely explanation for these differences in susceptibility are sex-and/or species-dependent differences in either overall rates of metabolism or distribution of metabolites among specific pathways. An understanding of the factors that determine these susceptibilities is essential for being able to extrapolate animal data to humans. An additional point, however, is that these sex-and species-dependent differences are often dose dependent in that markedly different types of effects may be seen at high versus low doses.
Overall rates of TCE metabolism vary considerably between the various experimental species that are used in laboratory investigations (i.e., rats, mice, rabbits) and between these species and humans (64) . In practical terms, more complete documentation and understanding of sex-and species-dependent differences in metabolism will enable refinements in risk assessment (35, 64, 65) , so that default assumptions can be significantly different than the actual situation in humans. However, the observed variations are often beyond allometric expectations, suggesting that more complex metabolic and other differences exist between species.
As described earlier, studies by Prout et al. (7) showed that blood levels of the TCE metabolites TCOH, CH, and TCA were severalfold higher in B6C3F1 mice than in Osborne-Mendel rats after a single oral dose of TCE. Larson and Bull (54) similarly showed that the initial rates of TCE metabolism to TCA were much higher in mice than in rats, leading to higher TCA concentrations in blood. Nakajima et al. (42) also showed that rates of oxidative metabolism of TCE in liver microsomes of male B6C3F1 mice were 2-to 3-fold higher, depending on dose, than those from male Wistar rats. Furthermore, overall content of P450 (nmol P450/mg microsomal protein) did not differ in the two species. Rather, the higher rate of TCE metabolism was due specifically to higher levels of CYP2E1 in mouse liver microsomes. In general, metabolic rates for most chemicals are significantly higher in mice than in rats or other larger animals, including humans.
A comparison of kinetic parameters for overall P450-catalyzed metabolism of TCE in liver microsomes from male B6C3F1 mice, F344 rats, and humans is shown in Table 4 . Several species-dependent differences are immediately apparent. First, kinetics were clearly biphasic in liver microsomes from rat and human but were monophasic in liver microsomes from mouse. Rates of TCE oxidative metabolism for the high-affinity processes were approximately 2-to 2.5-fold faster than those for the low-affinity processes in rats and humans. Finally, the ratio of V,,
to Km values, which is a measure of catalytic efficiency, shows that although rates are lower than in the other species, the activity in humans exhibits similar efficiency to that in rats and mice.
This similarity between rats and humans regarding P450-dependent metabolism of TCE may extend to other aspects of the metabolic process. Both the rat and human 2E family contain only one gene and expression of CYP2E1 in both species is regulated both transcriptionally and posttranscriptionally (65) . In contrast, the rabbit 2E subfamily comprises two genes. Although rabbit CYP2E1 appears to be very similar to human and rat CYP2E1 with respect to substrate specificity and regulation of expression, rabbit CYP2E2 is not coordinately controlled with CYP2E1 and developmental expression of the two forms differs. Thus, Wrighton and Stevens (65) and Lipscomb et al. (66) concluded that the rat is a better model than the rabbit for study of human CYP2E1 expression. The data summarized above, comparing P450-dependent metabolism of TCE in rats, mice, and humans, support this conclusion and indicate further that the rat is a better model than the mouse for study of oxidative metabolism of TCE in humans.
Although sex-dependent differences have been clearly observed in the susceptibility to TCE-induced toxicity and carcinogenicity, few studies of sex dependence ofTCE metabolism have been conducted. Nakajima et al. (41) studied sex-, age-, and pregnancyinduced effects on the expression and regulation of CYP2E1 and CYP2C1 1 with regard to TCE and toluene metabolism in Wistar rats. They observed no sex-dependent differences in TCE metabolism. The only differences in rates ofTCE metabolism to CH that were observed were an approximately 3-fold decrease from 3 weeks of age (puberty) to 18 weeks of age (maturity) in both sexes and a nearly 2-fold decrease in rates in females during pregnancy.
Variations among Humans
Lipscomb et al. (64) observed considerable variability in the P450-catalyzed oxidation of TCE in 23 samples of human liver microsomes. Km values for TCE (28.3 ± 12.9 pM; mean ± SD, n = 23) varied over a more than a fourfold concentration range (range = 12.6-55.7 pM) and were not normally distributed. Vmax values for CH formation (1,589 ± 840 pmol/min/mg; mean ± SD, n = 23) also showed considerable variability, with samples from individual human livers exhibiting a 7-fold range of values (range = 490-3,455 pmol/min/mg). In their analysis of the kinetics of TCE metabolism, individual samples seemed to cluster into three groups, having Km values (pM TCE, mean ± SD) of 16.7 ± 2.5 (n = 10), 30.9 ± 3.3 (n= 9), and 51.1 ± 3.8 (n = 4). Within each group, there were no patterns with regard to the ethnic group or sex of the donor from whom the livers were isolated, and Vm,, values in each group exhibited the same degree of variability and span of values as the entire sample pool. The Km value in females (21.9 ± 3.5 pM; n = 10) were significantly lower than that in males (33.1 ± 3.5 pM; n = 13).
Analysis of the activity of three specific P450 isoforms that are known to catalyze TCE metabolism in human liver microsome samples from the three groups revealed some patterns (Table 5 ). CYP1A2 activity was significantly lower in the low-Km group than in the other two groups, and CYP2E1 activity was significantly higher in the high-Km group than in the two other groups, but no differences were observed for CYP3A4 activity among the three groups. Lipscomb et al. (64) also found that CYP2E1 was the primary isoform responsible for TCE metabolism, accounting for > 60% of total microsomal metabolism. These results indicate that the capacity of humans to metabolize TCE will vary considerably and that factors that alter P450 activity, in particular CYP2E1 activity, can alter TCE metabolism and hence, susceptibility to TCE-induced toxicity. Nakajima et al. (41) (11, 52, 60, 64, 67, 68) . Data indicate a) that human hepatic microsomes possess less activity toward TCE than either rat or mouse hepatic microsomes, b) that TCOH formation proceeds at higher rates than TCA formation at low CH concentrations in all three species, and c) that appreciable levels of TCOH and TCA are formed from CH in the blood of all three species in vitro. The formation of DCA has been questioned for years, and no mechanism for its formation has been fully validated. DCA has not been identified in liver preparations (i.e., microsomes, homogenates, tissue slices) from mice or humans exposed to TCE, CH, or TCOH in vitro. Cultured gut microflora from mouse cecum produce DCA from TCA in a dose-and time-dependent Maiorino et al. (69) . Neither TCA nor DCA was detected (detection limit = 1.5 nmol/mL) under these conditions. Because CH is further metabolized to TCOH, CH and TCOH that were quantitated in microsomal incubations dosed with TCE were combined to give an estimate ofTCE metabolism.
Significant differences between the three species were found in the Michaelis-Menten kinetic parameters evaluated for CH formation from TCE. Overall kinetic parameters for TCE metabolism in rat, mouse, and pooled human liver microsomes (Table 6 (11) . These data provide further support for the involvement of CYP2E1 in TCE metabolism in the human. The high degree of conservation of CYP2E1 across mammalian species and the high degree to which it is expressed in rodent liver, compared to human liver, make the determination of inherent CYP2E1 activity and the assessment of factors that modify CYP2E1 expression in the human important considerations in population risk assessments. To determine the variability of CYP2E1 and gain an indication of the potential variability of TCE metabolism in the human, microsomal metabolism of CZX and the degree of expression of total P450 content was examined in 54 human hepatic microsome samples ( Figure 3 ). Data indicate that there is an approximate 5-fold variability in the expression of CYP2E1-dependent CZX metabolism in this population. Because of the degree of correlation of TCE metabolism with CYP2E1-dependent activity, it may be reasonably predicted that this degree of variability in TCE metabolism will be seen in the human population. Such variation and factors that induce the activity of CYP2E1 may define segments of the population that may be at a higher risk than would be otherwise anticipated (73) .
The data also indicate that other enzymes may metabolize TCE in the human. Because a high fraction of P450 is accounted for by CYP3A4 and CYP1A2 (72), the effect on TCE metabolism of known substrates for these forms was evaluated. a-Napthoflavone (a CYPIA substrate) and ketoconazole (a CYP3A substrate) did not inhibit TCE metabolism when assessed at TCE concentrations near the Km value (64) Table 7 indicate that clearance of CH to TCOH is much higher (10- Clearance of CH to TCA in the mouse and human were similar, whereas it was approximately 10-fold lower in the rat. These data indicate that TCOH formation will predominate over TCA formation in the liver of these three species. The kinetic evaluation of TCOH production also revealed that the mouse may have two separate enzymes (Table 7) . It is doubtful whether CH will attain concentrations in human liver to drive metabolism near the theoretical maximal value. Km values (CH) for TCA are much higher than those required for TCOH production, indicating that low concentrations of CH will favor the production of TCOH. Km* values (mM NAD+) for TCA production were 0.13 and 0.14 mM for the rat and mouse, respectively.
The kinetic parameters indicate that at low hepatic concentrations of CH (below 0.5 mM), TCOH will be the preferred hepatic metabolite. As shown in Table 8 , the predicted ratio of TCOH:TCA is 10 to 20, depending on species. These predictions agree well with the observed urinary elimination of TCOH and TCA in mice and rats exposed to 200 mg TCE/kg (53, 54) and with initial (0-1 hr) plasma levels of metabolites observed in CH-exposed humans, where the levels of TCOH were slightly higher than plasma levels (79, 80) . Figure 1 , the other possible fate of TCE besides oxidative metabolism is conjugation with GSH, which is catalyzed by the GSTs. GSTs, like P450s, comprise a family of isoforms. With the exception of the microsomal GST isoform, all other isoforms are cytosolic. The primacy of the liver as the site of GSH conjugation is highlighted by the observation that GST protein can comprise as much as 5% of the total cytosolic protein in rat or human liver. However, GSTs are present in most tissues, including the kidneys, so that this initial step in the pathway does not necessarily have to occur in the liver but can also occur in the target organ.
S-(1,2-dichlorovinyl)glutathione (DCVG). As shown in
The cysteine conjugate of TCE, S- processed by y-glutamyltransferase (GGT) to the cysteinylglycine conjugate S-(1,2-dichlorovinyl)-L-cysteinylglycine (DCVCG) and then by various membrane-bound One strategy to validate the function of the GSH conjugation pathway in bioactivation and toxicity has been to use either cosubstrates that are specific for particular steps to potentiate activity or toxicity or to use specific inhibitors of enzymatic steps to inhibit pathway flux or toxicity. If the GSH conjugation pathway is responsible for bioactivation and toxicity, then cosubstrates should enhance toxicity and specific inhibitors should diminish toxicity. As summarized in Figure 5 , this strategy has been applied to DCVG and its metabolites in both in vivo experiments (85) and in vitro studies with suspensions of isolated rat kidney cells (91 (99) (100) (101) (102) (103) , intestinal microflora (104, 105) , and rat brain (106, 107 ,B-lyase-mediated catalysis by the intestinal microflora, these enzymes are not thought to play a significant role in DCVC metabolism and no intestinal toxicity is seen with administration of DCVC. As discussed below in the section on tissue distribution of I-lyase activity, the hepatic P-lyase activity is associated with kynureninase (100) and is distinct from the renal I-lyase activities (108) , whereas the renal 13-lyase activity is a catalytic property of glutamine transaminase K (109-116). Alberati-Giani et al. (106) reported that rat liver also expresses the mRNA for the renal glutamine transaminase K but that the levels of the mRNA in the liver are much lower than those in the kidneys. Due to the patterns of interorgan metabolism and the tissue specificity of enzymes that process GSH conjugates and related metabolites, hepatic kynureninase does not appear to play a role in DCVC metabolism and no liver pathology is observed after treatment of rats with DCVG or DCVC (85, 86, 99) . Hence, it is the renal P-lyase activities that are critical for DCVC bioactivation.
The initial 3-lyase activities that were purified from rat (115) and human (113) (122, 123) suggested that measurement of the acid-labile adducts could be used as an index of flux through the ,B-lyase pathway. While this would seem to make sense, as it is the quantity of the reactive species that is formed that can produce cellular injury and not, as discussed below, the quantity of stable endproducts that are excreted into the urine (e.g., mercapturates), the methodology is potentially complicated by artifacts due to chemical instability of the molecules being quantified. Additionally, Eyre et al. (122, 123) found that apparent net activation of TCE by the 1-lyase pathway and apparent acid-labile adduct formation were greater in mice than in rats, which does not correspond to the higher susceptibility of rats to renal toxicity and carcinogenesis, although adduct formation did correspond to increased cell replication rates. Hence, the relationship between adduct formation and effects on cellular function and homeostasis are very complex and require further study.
MacFarlane et al. (124) showed that pretreatment of rats with a single, subtoxic dose of the mercapturate of a nephrotoxic halogenated hydrocarbon produced a 1.5-to 3- fold increase in renal 1-lyase activity and an increase in the cognate mRNA. These results suggest that prior or continuous exposures to low, subtoxic doses of certain cysteine or Nacetylcysteine conjugates may enhance the capability to generate reactive species by the P-lyase after subsequent exposures to toxic doses of these conjugates or their precursors. Although little is currently known about the genetic regulation of the 1-lyase, these data suggest that differential expression of the 13-lyase may need to be taken into account in a risk assessment for chemicals whose nephrotoxicity is mediated by this enzyme. Sulfoxides are known metabolites of cysteine conjugates that can be recovered in the urine as stable end products. Elfarra and colleagues (128, 129) identified and subsequently purified an enzymatic activity from rat liver and kidney microsomes that metabolizes DCVC to its sulfoxide. This enzyme was subsequently shown to be a flavin-containing monooxygenase (FMO), initially thought to be related to FMOIA1 (129) , but more recent data suggest that FMO3 is the isoform responsible for DCVC oxidation (130) . Unlike other cysteine conjugate sulfoxides, DCVC sulfoxide is unstable and reacts with cellular nucleophiles, including GSH (131) . The potential significance of this activity for overall TCE or DCVC bioactivation and for human health risk assessment is undear, but DCVC sulfoxide was shown to be markedly more nephrotoxic to rats and more cytotoxic in freshly isolated rat renal cells than DCVC (132) . This finding warrants further investigation.
Werner et al. (133) recently showed that sulfoxides can arise by a different pathway. In their studies, they found that NAcDCVC and the mercapturate of perchloroethylene (PER) were metabolized by rat liver microsomes to the corresponding sulfoxides by CYP3A and not by an FMO. These investigators also found that the N-acetylcysteine conjugate sulfoxides were markedly more cytotoxic in freshly isolated rat renal cortical cells than the corresponding mercapturates, similar to the situation with cysteine conjugate sulfoxides. This report adds an additional dimension to known bioactivation mechanisms of DCVC. Due to the efficient processing of mercapturates by the liver, which leads to their delivery to the kidneys, and the much lower activity of CYP3A in the kidneys as compared with the liver, this pathway is not likely to be quantitatively important overall or even in comparison to the P-lyase pathway.
An additional although minor fate of the reactive DCVSH generated by the ,-lyase and other enzymes is methylation, which occurs by a thiomethyltransferase in the intestinal microflora (134) . The thiomethyltransferase uses S-adenosylmethionine to transfer a methyl group to the thiol, forming the methylthio derivative, which is subsequently oxidized to the methylsulfinyl (CH3SO-) and methylsulfonyl (CH3SO2-) analogs. The methylthio derivatives are nonpolar and are generally excreted into the feces. Quantitatively, this pathway is probably minor for TCE, accounting for no more than 0.05-0.1% of the total excreted metabolites ofTCE.
Membrane transport of GSH-derived metabolites of TCE. Membrane transport processes play an important role in the tissue distribution of the various GSH conjugates and related metabolites [ (89); also see discussion below on interorgan metabolism). There are three GSH-derived metabolites of TCE whose membrane transport is important for understanding tissue distribution: DCVG, DCVC, and NAcDCVC. For DCVG, both efflux from the hepatocyte and membrane transport processes in renal proximal tubular cells are toxicologically important. For both DCVC and NAcDCVC, uptake into renal proximal tubular cells is the relevant process.
As discussed above, there are two primary sources or sites of formation of DCVG-the liver and the kidneys. For DCVG that is generated by renal GSTs, further processing occurs by efflux of intracellular DCVG by transport across the brush-border membrane into the lumen, where it can then be metabolized by GGT and dipeptidases to generate DCVC. Efflux of GSH and GSH S-conjugates into the lumen by transport across the brushborder membrane is viewed as an essential step in the turnover of these compounds because the active site of GGT is extracellular (135) . In fact, inhibition of GGT in vivo produces marked glutathionuria in mice (135) . Presumably, a marked increase in urinary excretion of GSH conjugates would also occur under similar conditions. Although this transport step has not been specifically quantitated for DCVG, Inoue and Morino (136) determined the mechanism and kinetics of transport for GSH in renal brush-border membrane vesicles. GSH uptake was dependent on the membrane potential and exhibited a Km for GSH of 0.21 mM and a V,, of 1.15 nmol/min per mg protein. It can be expected that brush-border membrane DCVG transport will likely exhibit similar kinetics.
For DCVG that is generated in the liver, there are two additional steps, efflux across the canalicular membrane into the bile or across the sinusoidal membrane into the plasma, and extraction by the kidneys. Hepatic GSH conjugates are transported primarily into bile by the canalicular multispecific organic anion transporter (cMOAT), which is an ATPase that mediates efflux of various GSH conjugates and organic anions (137) (138) (139) (140) Besides the luminal transport of DCVG, plasma DCVG that does not undergo glomerular filtration may gain access to the renal proximal tubular cell by transport across the basolateral plasma membrane (142) . This transport occurs by the Na+-coupled system described for GSH (143, 144) . Transport of both GSH and GSH S-conjugates is inhibited by probenecid and p-aminohippurate, suggesting that the organic anion carrier may be involved in the transport. Another study on renal plasma membrane GSH transport (145) indicates the additional involvement of plasma membrane dicarboxylate carriers. Rates of DCVG transport into membrane vesicles were extremely rapid (22 nmol/min/ per mg protein with 5 mM DCVG) and transport was inhibited by GSH and y-glutamyl amino acids, but not by DCVC (142) . Once inside the renal proximal tubular cell, DCVG will be translocated to the brush-border membrane for efflux into the lumen and metabolism as described above.
Once DCVG is secreted into the bile, a significant portion of it will be metabolized by either biliary or intestinal GGT and dipeptidases to form DCVC. The transport processes relevant for DCVC include uptake into the hepatocytes (enterohepatic circulation) and uptake into the renal proximal tubular cell. Again, little data are available on rates of DCVC transport into the liver, with the exception of one in vitro study. Simmons et al. (146) characterized DCVC uptake by isolated canalicular membrane vesicles from rat liver. DCVC uptake was Na+ independent and exhibited Km and Vm,, values of 155 ,uM and 4.7 nmol/min per mg protein, respectively. This step thus appears to have a greater capacity than any of the steps for DCVG transport.
Renal extraction of plasma DCVC can occur by either glomerular filtration and uptake across the brush-border membrane or by uptake across the basolateral membrane. Transport across the brush-border membrane from rat kidney cortex was reported to be Na+ dependent and exhibited Km and V, values of 225 pM and 3.1 nmol/min per mg protein, respectively (147) . In contrast, Wright et al. (148) found that DCVC uptake in brush-border membrane vesides from rabbit renal cortex was Na+-independent and exhibited Km and V, values of 0.45 mM and 60 nmol/min per mg protein. Brush-border membrane transport of DCVC was unaffected by NAcDCVC or several other organic anions but appears to occur by the same carrier that transports neutral amino acids such as phenylalanine. In contrast to this, basolateral transport of DCVC occurs by both Na+-dependent and Na+-independent mechanisms and the Na+-dependent process interacts with the transport of NAcDCVC and organic anions (149, 150) . Rates of DCVC uptake by isolated renal proximal tubular cells, which reflect primarily transport processes occurring at the basolateral membrane, were approximately 2-fold higher for DCVC than for DCVG (142, 150) . Thus, as with canalicular membrane transport, renal transport of DCVC appears to be significantly faster than that of DCVG. After release from the hepatocyte, DCVG will undergo interorgan translocation and/or metabolism. In its translocation to the kidneys, a portion of it will first be returned to the liver before efflux into plasma (renalhepatic circulation). Some of the DCVG will be metabolized extrahepatically to DCVC and some of this will be N-acetylated, either extrahepatically or in the liver to form NAcDCVC. Hence, the mercapturate is also a form to which the kidneys are exposed. Transport of NAcDCVC into renal proximal tubular cells occurs readily and presumably by the organic anion carrier (93, 94) . Kinetic parameters for transport at specific membrane sites are unavailable, but estimates appear to be similar to those for DCVC. Transport of NAcDCVC is not believed to be limiting for nephrotoxicity, as described above. Rather, the intracellular deacetylation reaction likely determines the extent of regeneration of DCVC and the degree of cytotoxicity.
Tissue Distribution and Sex-and Species-Dependent Heterogeneity ofGSH-Dependent Metabolism ofTCE
The selective tissue distribution of the various enzymes of the GSH-dependent metabolism of TCE plays a critical role in determining the target organ specificity of DCVC and the reactive species that are derived from its further metabolism. Hence, a precise knowledge of the relative activities of each of the major enzymes of the pathway is important, to help both in understanding how toxicity occurs and in assessing the relevance of the GSH conjugation pathway relative to the oxidative pathway in TCE-induced toxicity. The liver and kidneys are the major sites of GSH-dependent metabolism of TCE, although biliary and intestinal metabolism also play significant roles.
Although most cell types express some GST activity, the liver is by far the predominant site of GSH conjugation. Table 13 summarizes measurements of GST activity with 1-chloro-2,4-dinitrobenzene as substrate in cytosolic fractions from male and female F344 rat and B6C3F, mouse liver and kidney. With the exception of the female rat, specific activities (normalized to protein) are slightly to modestly lower in kidney cytosol than in those from liver cytosol. However, total activity in the liver will be much higher than in the kidneys due to the larger tissue size.
For chemicals such as TCE that undergo GSH conjugation and eventually are translocated to the kidneys for further metabolism, it has generally been assumed that most if not all of the GSH conjugation occurs in the liver. However, Lash et al. (151) showed that TCE is conjugated with GSH in freshly isolated kidney cells from male F344 rats, although at rates that are only 5 to 10% of those in isolated hepatocytes (Figure 7 ). Koob and Dekant (152) also demonstrated that hexafluoropropene, a nephrotoxic fluoroalkene, can undergo GSH conjugation in the kidney as well as in the liver. Thus, the entire GSH conjugation pathway can occur within the target tissue. Although the majority of the flux involves interorgan processes (see below), with the liver catalyzing the majority of the initial step in the pathway, this intraorgan process should be taken into account in refinements of PBPK models and risk assessments for TCE.
A summary of measurements of DCVG formation from TCE in liver and kidney cytosol and microsomes from male and female F344 rats and B6C3F, mice (153, 154) is given in Table 14 . The results show some dramatic sex-and species-dependent differences in GSH conjugation of TCE. Although overall GSH conjugation in male rats is clearly higher than that in female rats, no detectable DCVG formation was observed in male rat liver microsomes, whereas DCVG formation in female rat liver microsomes occurred at approximately twice the rate as in the cytosol. Rates of metabolism in mice in both kidney and liver fractions were also generally faster in males than in females and were markedly higher than corresponding rates in Environmental Health Perspectives * Vol 108, Supplement 2 * May 2000 rats. This last point brings up an interesting correlation with the covalent adduct formation reported by Bull and colleagues (93,94) . As summarized above, 2-fold higher rates of covalent adduct formation from 35S-labeled DCVC were found in mouse kidney compared to those in rat kidney. Hence, both higher rates of adduct formation and GSH conjugation of TCE occur in the mouse kidney, although the rat is the species in whom renal tumors are observed.
Kinetics of GSH conjugation of TCE in subcellular fractions from pooled human liver and kidney samples are summarized in Table 15 . Although analysis could only detect a single, kinetically distinct process for DCVG formation in kidney fractions, GSH conjugation of TCE in both liver cytosol and (154) were unable to detect net, enzymatic formation of DCVG in incubations with rat kidney subcellular fractions. In contrast, Lash and colleagues (151, 153) reported a rate of DCVG formation in incubations of male rat kidney cytosol with 2 mM TCE and 5 mM GSH of 7.5 pmol/min per mg protein and a rate of 0.7 nmol/min per mg protein in pooled human kidney cytosol (154) .
The controversy between these results has not been resolved. Differences in analytical methods (radiolabeled substrate with high performance liquid chromatography (HPLC) separation versus derivatization and HPLC (151, 153) showed the expected saturation kinetics and maximization versus incubation time of an enzyme-catalyzed process.
Measurements of GGT activity in liver and kidney subcellular fractions from male and female rats and mice and pooled human liver and kidney samples show clearly that at least in rodents, insignificant GGT activity is present in the liver (Table 16 ). Human liver exhibits relatively low activity of GGT (approximately 3% of that in the kidneys). Only modest sex-dependent differences were observed in GGT activity. Rats exhibited the highest activity of GGT, with humans exhibiting approximately 50% of that in rats and mice exhibiting only 20% of that in rats. Higher GGT activity provides more substrate for the P-lyase reaction, which would generate higher amounts of reactive species. Hence, these differences may contribute to speciesdependent differences in overall flux of TCE through the GSH conjugation pathway.
Hinchman and Ballatori (156) compared renal and hepatic GGT activity in several mammalian species. Although the kidneys contain the highest levels of GGT activity in all species examined, including humans, specific activities (i.e., mU/mg protein) can vary up to 10-fold or more between species. Furthermore, although adult liver contains relatively low levels of GGT activity, specific activities can also vary up to 10-fold or more. Hence, while the ratio of GGT specific activity in kidney to that in liver was reported as 875 in rats and 413 in mice, it was only 100 in rabbits and 19 in pigs. Humans exhibit tissue distributions similar to rabbits. Use of rats to model 4 experiments for mice, and 3-9 measurements from humans, except for human kidney microsomes, which is the average of 2 measurements. Data reported in (153, 155) .
GSH conjugates on renal basolateral membranes and the absence of an uptake system in liver cell plasma membranes.
GSH conjugation of TCE was demonstrated in isolated human hepatocytes ( Figure 9 ). Rates of DCVG formation, although lower than those in rat hepatocytes by approximately 2-to 3-fold, were not so low or difficult to detect that one would conclude that flux through the GSH conjugation pathway is too low to account for a measurable and possibly significant portion of total TCE metabolism. Of course, this is only the initial step in the pathway with subsequent branches leading to excretion of nontoxic products in addition to the branches that produce toxic metabolites. Hence, it is critical to quantitate formation of the metabolites that directly produce cellular injury.
As emphasized above, the key step in the bioactivation of TCE by the GSH conjugation pathway is the ,-lyase step. Reports of ,-lyase activity in the literature show a fair amount of variability, depending in part on the cysteine conjugate substrate used, the assay method used, and even the laboratory reporting the data. were isolated from livers of human donors and were incubated in sealed flasks with the indicated concentration of TCE in the headspace for 120 min. DCVG formation was assayed in perchloric acid extracts of aliquots of cells by ion-exchange, reversed-phase high-performance liquid chromatography after derivatization with iodoacetate and 1-fluoro-2,4-dinitrobenzene. Derivatives were detected spectrophotometrically at 365 nm and were quantified with respect to authentic standards. Data reported in (155) .
rats to kidney toxicity and cancer than other species. Km and Vmax values for male rats were also lower and higher, respectively, than those for female rats, which is consistent with male rats being more susceptible than female rats. The central questions for risk assessment, therefore, are: a) Can studies in male rats be extrapolated to humans? and b)
Is P-lyase activity in human kidney high enough to generate sufficient amounts of reactive metabolites to produce nephrotoxicity and kidney cancer? Additional studies are clearly necessary to accurately determine flux through this pathway. Elfarra and Hwang (158) used the model cysteine conjugate S-(2-benzothiazolyl)-L-cysteine (BTC) as an in vivo marker of flux through the 3-lyase pathway. BTC was originally synthesized as a convenient assay substrate for the P-lyase (99) Hence, the relative proportion of metabolites formed will likely vary markedly at low versus high doses. Specifically, CYP2E1 saturates at significantly lower doses of TCE than do the GSTs, suggesting that flux of TCE through the GSH conjugation pathway may only be quantitatively important at higher doses of TCE. As mentioned earlier, however, the GSH conjugation pathway, and specifically the i-lyase reaction, generates chemically reactive metabolites; formation of even a small amount of a reactive species may be sufficient to produce alterations in cellular function whereas formation of relatively large amounts of a non-reactive metabolite may not produce any cellular dysfunction.
Hence, although one may conclude by intuition that a low-affinity pathway may only be of toxicological importance at high doses and/or when the high-affinity pathway is saturated, this is not necessarily correct for a pathway such as that catalyzed by the ,1-lyase that generates chemically unstable and reactive metabolites. It has been argued that the ,B-lyase pathway is not quantitatively important for humans, based on the following points: a) Kinetic parameters (i.e., affinity and capacity) of the I-lyase in human kidney, as compared to those for P450 oxidation in human liver, are such that P-lyase activity will only become quantitatively significant at extremely high exposure levels; b) TCE exposure studies comparing excretion of mercapturate to that of TCA and TCOH show that the P450-derived metabolites are recovered in urine at levels that are two to three orders of magnitude higher than the GSH-derived metabolite; and c) questions have arisen about the relevance of reports of kidney tumors in human populations exposed to TCE. I will discuss the first two points below. The third point will be only briefly discussed, as this is dealt with in greater detail in the kidney mode of action review (89) .
Concerning the first point about the relative kinetic parameters of the oxidative and GSH conjugation pathways, there is no doubt that flux through the P450 pathway is much faster and that the total capacity is much greater than for the GSH conjugation and P-lyase reactions. There are two major differences between the nature of the metabolites formed by the two pathways. First, the various enzymes of the GSH conjugation pathway and the membrane transporters for GSH and cysteine conjugates and mercapturates exhibit significant tissue heterogeneity so that metabolites are directed to the kidneys for intracellular accumulation and metabolism to reactive species. Second, the metabolites from the GSH conjugation pathway that are believed to be responsible for effects in the kidneys are chemically unstable and highly reactive whereas those derived from the oxidative pathway are relatively stable. Because (Table 19 ). However, even in the studies that show lower ratios of oxidative metabolites (TCA or TCA + TCOH) to NAcDCVC, it has been argued that ratios as little as 10:1 indicate that the flux through the GSH conjugation pathway is at least an order of magnitude slower than that through P450. It must be emphasized, however, that measurement of urinary mercapturate provides only an indication of a portion of the GSH-dependent pathway and that this portion is not related to that which is associated with nephrotoxicity and nephrocarcinogenicity. Measurement of urinary mercapturates, therefore, can give an indication of exposure and that some flux through the GSH conjugation pathway has occurred. It cannot, however, give an indication of total flux through the GSH conjugation pathway or through that portion of the pathway that leads to effects on renal function. Moreover, formation of even a small amount of reactive species may be sufficient to produce toxic effects or changes in intracellular regulatory mechanisms.
Concerning the third point about the occurrence of kidney tumors being much lower than those in the other target organs and this relating to a small flux through the GSH conjugation and P-lyase pathways, the following points should be noted: a) the background rate of kidney tumors is extremely small in humans and most animal species studied (although some strains of rats show a relatively high background rate); b) the kidneys are particularly susceptible to cytotoxic injury from even brief, low-dose exposures to nephrotoxicants; and c) proximal tubular epithelial cells can undergo a program of apoptosis and regeneration after exposures to sublethal doses, or even necrotic doses, of nephrotoxicants. These points should highlight the difficulties in assessment of factors involved in induction of renal carcinogenesis.
Although species-and sex-dependent differences are found in various steps of TCE metabolism, it is important to also consider the entire pathway as a whole and not just individual reactions. Although the rate of a specific step may be relevant to a consideration of toxicity if the toxicity is solely dependent on the formation of a specific metabolite, the balance between metabolite formation and subsequent metabolic steps and species differences in the ratio of these steps are often of more importance.
In summary, it is clear that the oxidative pathway is quantitatively the more important of the two major pathways of TCE metabolism. However, the interorgan patterns of the GSH-dependent pathway and the chemical nature of the critical metabolites generated by the two pathways greatly alters the importance of simple comparisons of quantitation. Furthermore, we do not really have an accurate method to assess flux through all branches of the GSH-dependent pathway because chemically reactive species are generated. Almost all of the focus of TCE metabolism in the kidneys has been on the GSHdependent pathway. Although there is no direct evidence to suggest that intrarenal formation of metabolites such as TCA or DCA is involved in the renal effects of TCE, this issue has not been investigated fully so we should not a priori rule it out.
GST Isozyme Distribution andVariation
Recent work has revealed that the various GSTs exist in isozymic forms and that sex-, species-, and tissue-dependent differences often exist. The substrate specificity of these isozymes and specifically the activity of each isozyme toward TCE is unknown at present. Briining et al. (162) have recently shown that genetic polymorphisms exist in two GSTs, GSTM1 and GSTT1, and that differences in expression of these isozymes may have toxicological significance for TCE bioactivation by this pathway. Hence, work is needed to define the isozyme composition in various species, including humans, and in various tissues in each species, and to define the activity of each isozyme towards TCE.
Quantitative Importance ofDCVC Metabolism in Humans
The difficulties in assessing the quantitative importance of flux through the GSH conjugation pathway, and through the ,-lyase reaction specifically, have been discussed above in some detail. Three key issues are * Improved measurements of overall 
